ABBV 382
Alternative Names: ABBV-382Latest Information Update: 15 Oct 2024
Price :
$50 *
At a glance
- Originator AbbVie
- Class Anti-inflammatories; Antiretrovirals; Monoclonal antibodies
- Mechanism of Action Alpha4beta7 integrin antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Crohn's disease; HIV-1 infections
- Phase I Unspecified
Most Recent Events
- 08 Oct 2024 Phase-I clinical trials in Unspecified (In volunteers, In adults) in China (IV) (NCT06632938)
- 08 Oct 2024 Phase-I clinical trials in Unspecified (In volunteers, In adults) in China (SC) (NCT06632938)
- 04 Sep 2024 Phase-II clinical trials in Crohn's disease (Combination therapy) in USA (IV), (NCT06548542),